Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting

World News: . []

BERKELEY Calif May 16 2018 GLOBE NEWSWIRE -- Dynavax Technologies Corporation NASDAQDVAX announced today that data will be presented from its ongoing Phase 1b2 study investigating SD-101 Dynavaxs intratumoral TLR9 agonist, in combinati on with...

More news and information about Dynavax Technologies Corporation

Published By:

Globe Newswire: 22:15 GMT Wednesday 16th May 2018

Published: .

Search for other references to "dynavax" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us